Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection

Open Forum Infectious Diseases

Volumn 5, Issue 4, 2018, Pages

  LaVergne, Stephanie ^a,c   Hamilton, Theron ^b   Biswas, Biswajit ^b   Kumaraswamy, M ^a   Schooley, R T ^a   Wooten, Darcy ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteriophage; Multidrug resistance; Phage

Indexed keywords

AZITHROMYCIN; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CREATININE; DORIPENEM; ENDOTOXIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIOPHAGE; BACTERIUM ISOLATION; BLOOD CELL COUNT; CASE REPORT; CLINICAL ARTICLE; COLONY FORMING UNIT; CRANIECTOMY; DEBRIDEMENT; DRUG APPROVAL; DRUG WITHDRAWAL; ENCEPHALITIS; FEVER; FRACTIONAL INHIBITORY CONCENTRATION INDEX; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; LEUKOCYTOSIS; LIVER FUNCTION TEST; MALE; MIC90; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII; PHAGE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN FLAP; SURGICAL INFECTION;

EID: 85054931439     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy064     Document Type: Article

References (11)

1. Centers for Disease Control and Prevention. Antibiotic/Antimicrobial Resistance. Available at: cdc.gov/drugresistance/index.html. Accessed 11 October 2017.
2. Zaman SB, Hussain MA, Nye R, et al. A review on antibiotic resistance: alarm bells are ringing. Cureus 2017; 9:e1403.
3. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 2011; 1:31-45.
4. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45:649-59.
5. Dubos RJ, Straus JH, Pierce C. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with shigella dysenteriae. J Exp Med 1943; 78:161-8.
6. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophages therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009; 18:237-8; 240-83.
7. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34:349-57.
8. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 2017; 61:e00954-17.
9. Sambrook J, Fritch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
10. Ormälä AM, Jalasvuori M. Phage therapy: Should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 2013; 3:e24219.
11. Pelfrene E, Willebrand E, Cavaleiro Sanches A, et al. Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 2016; 71:2071-4.